Bulletin
Investor Alert

New York Markets Close in:

Invitae Corp.

NYS: NVTA

GO
/marketstate/country/us

Market open

/zigman2/quotes/203200150/composite

$

0.68

Change

-0.02 -2.81%

Volume

Volume 5.49m

Sep 22, 2023, 1:27 p.m.

Real time quotes

/zigman2/quotes/203200150/composite

Previous close

$ 0.70

$ 0.68

Change

-0.02 -2.81%

Day low

Day high

$0.67

$0.71

Open
Open: 0.71

52 week low

52 week high

$0.67

$3.78

Open

Market cap

$186.43M

Average volume

10.58M

P/E ratio

N/A

Rev. per Employee

$290,516

EPS

-3.23

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/nvta

MarketWatch News on NVTA

  1. Will AI save money-losing tech stocks from the short-sellers?

    11:30 a.m. June 10, 2023

    - Jeffrey Lee Funk

  2. Invitae downgraded to underperform from market perform at Raymond James

    7:38 a.m. May 15, 2023

    - Tomi Kilgore

  3. How Illumina’s Big Bet on Cancer Screener Grail Went Wrong

    9:30 p.m. Sept. 9, 2022

    - Barron's Online

  4. Invitae downgraded to underweight from neutral at J.P. Morgan

    7:11 a.m. Aug. 11, 2022

    - Tomi Kilgore

  5. Invitae downgraded to market perform from outperform at Raymond James

    8:41 a.m. July 21, 2022

    - Tomi Kilgore

  6. Invitae downgraded to hold from buy at Benchmark

    6:06 a.m. July 19, 2022

    - Tomi Kilgore

  7. Invitae stock price target cut to $13 from $35 at Benchmark

    8:18 a.m. Feb. 7, 2022

    - Tomi Kilgore

  8. Cathie Wood Likes Tesla. But Her ARK Funds Keep Selling the Stock.

    4:13 p.m. Sept. 16, 2021

    - Barron's Online

  9. 5 Biotech Stocks That Could Lead a Revival

    2:05 p.m. Sept. 6, 2021

    - Barron's Online

  10. Will Illumina’s Purchase of Grail Kill Cancer-Test Competition?

    7:49 a.m. Aug. 30, 2021

    - Barron's Online

  11. Invitae upgraded to buy from hold at Benchmark

    6:25 a.m. Aug. 4, 2021

    - Tomi Kilgore

  12. How Natera Is Defending Its Lead in a $15B Cancer-Testing Market

    10:34 a.m. June 22, 2021

    - Barron's Online

  13. Invitae initiated at outperform with $37 price target at Raymond James

    7:45 a.m. June 15, 2021

    - Tonya Garcia

  14. How a Simple Blood Test Could Reduce Cancer Deaths

    7:26 a.m. April 12, 2021

    - Barron's Online

  15. SoftBank snaps up $2.8 billion stake in Norway robotics firm

    3:57 p.m. April 6, 2021

    - Lina Saigol

  16. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/nvta

Other News on NVTA

  1. 10-Q: INVITAE CORP

    5:09 p.m. May 9, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  2. 10-K: INVITAE CORP

    6:17 p.m. Feb. 28, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  3. Ark Invest Stages a Stunning Comeback as Inflation Numbers Ease

    5:55 p.m. Nov. 10, 2022

    - GuruFocus.com

  4. Invitae Corporation (NVTA) Q3 2022 Earnings Call Transcript

    10:00 p.m. Nov. 8, 2022

    - Seeking Alpha

  5. Invitae (NVTA) Reports Q3 Loss, Tops Revenue Estimates

    6:55 p.m. Nov. 8, 2022

    - Zacks.com

  6. 10-Q: INVITAE CORP

    6:02 p.m. Nov. 8, 2022

    - Edgar Online - (EDG = 10Q, 10K)

/news/pressrelease/company/us/nvta

Press Releases on NVTA

  1. Invitae to Appeal Trial Verdict

    4:07 p.m. May 15, 2023

    - PR Newswire - PRF

  2. Invitae Reports First Quarter 2023 Financial Results

    4:01 p.m. May 9, 2023

    - PR Newswire - PRF

  3. Invitae Announces Partnership with Epic to Streamline Genetic Testing

    7:30 a.m. March 21, 2023

    - PR Newswire - PRF

  4. Invitae to Present at the TD Cowen 43rd Annual Health Care Conference

    5:05 p.m. March 1, 2023

    - PR Newswire - PRF

  5. Invitae Reports Preliminary 2022 Financial Results

    8:00 a.m. Jan. 9, 2023

    - PR Newswire - PRF

Rates »

Link to MarketWatch's Slice.